Web appendix 4 – ~~The efficacy of eradication therapies for *H. pylori* and the assessment of publication bias~~

1. Efficacy assessment by intention to treat (ITT) analysis

Table S4.1 Network meta-analysis results

	Full analysis	Sensitivity analysis (publication year)	Sensitivity analysis (quality of included study)	Sensitivity analysis (sample size)
Intervention	**Risk Ratio (95% CrI), random-effect model**	**Risk Ratio (95% CrI), random-effect model**	**Risk Ratio (95% CrI), random-effect model**	**Risk Ratio (95% CrI), random-effect model**
7d triple				
7d concomitant	1.29 (1.22 to 1.35)	1.29 (1.21 to 1.35)	1.29 (1.21 to 1.35)	1.00 (0.99 to 1.01)
10/14d sequential	1.20 (1.16 to 1.23)	1.20 (1.16 to 1.24)	1.20 (1.16 to 1.23)	1.19 (1.15 to 1.23)
10/14d triple	1.12 (1.08 to 1.15)	1.12 (1.08 to 1.15)	1.11 (1.07 to 1.15)	1.11 (1.06 to 1.15)
10/14d bismuth	1.17 (1.12 to 1.21)	1.17 (1.12 to 1.22)	1.18 (1.13 to 1.22)	1.16 (1.11 to 1.22)
7d bismuth	1.08 (1.00 to 1.15)	1.08 (1.00 to 1.16)	1.08 (1.00 to 1.16)	1.08 (0.97 to 1.17)
10/14d concomitant	1.24 (1.19 to 1.29)	1.24 (1.19 to 1.29)	1.24 (1.18 to 1.29)	1.21 (1.14 to 1.27)
7d probiotic	1.14 (1.07 to 1.20)	1.14 (1.06 to 1.20)	1.14 (1.06 to 1.21)	1.14 (1.06 to 1.22)
10/14d probiotic	1.24 (1.17 to 1.29)	1.24 (1.17 to 1.30)	1.24 (1.17 to 1.30)	1.23 (1.13 to 1.31)
7d ranitidine bismuth	1.12 (1.04 to 1.18)	1.12 (1.04 to 1.19)	1.12 (1.04 to 1.19)	1.13 (1.03 to 1.21)
10/14d ranitidine bismuth	1.17 (1.07 to 1.25)	1.18 (1.07 to 1.26)	1.17 (1.07 to 1.25)	1.15 (1.02 to 1.25)
7d levofloxacin	1.04 (0.95 to 1.11)	1.04 (0.95 to 1.11)	1.04 (0.95 to 1.11)	1.04 (0.94 to 1.12)
10/14d levofloxacin	1.23 (1.16 to 1.29)	1.23 (1.16 to 1.29)	1.23 (1.15 to 1.29)	1.23 (1.14 to 1.30)
14d hybrid	1.22 (1.11 to 1.29)	1.22 (1.11 to 1.30)	1.21 (1.10 to 1.30)	1.20 (1.07 to 1.29)

Intervention	Full analysis	Sensitivity analysis (publication year)	Sensitivity analysis (quality of included study)	Sensitivity analysis (sample size)
	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model
7d concomitant				
10/14d sequential	0.93 (0.89 to 0.99)	0.93 (0.88 to 0.99)	0.93 (0.88 to 0.99)	1.19 (1.15 to 1.23)
10/14d triple	0.86 (0.82 to 0.92)	0.86 (0.82 to 0.92)	0.86 (0.81 to 0.92)	1.11 (1.06 to 1.15)
10/14d bismuth	0.90 (0.86 to 0.97)	0.90 (0.85 to 0.97)	0.91 (0.86 to 0.97)	1.16 (1.11 to 1.22)
7d bismuth	0.84 (0.76 to 0.91)	0.84 (0.76 to 0.91)	0.84 (0.76 to 0.91)	1.08 (0.97 to 1.17)
10/14d concomitant	0.96 (0.91 to 1.02)	0.96 (0.91 to 1.02)	0.96 (0.90 to 1.02)	1.21 (1.15 to 1.27)
7d probiotic	0.88 (0.81 to 0.95)	0.88 (0.81 to 0.95)	0.88 (0.81 to 0.96)	1.15 (1.06 to 1.22)
10/14d probiotic	0.96 (0.90 to 1.03)	0.96 (0.90 to 1.03)	0.96 (0.89 to 1.03)	1.23 (1.13 to 1.31)
7d ranitidine bismuth	0.86 (0.80 to 0.94)	0.87 (0.79 to 0.94)	0.87 (0.80 to 0.94)	1.13 (1.03 to 1.21)
10/14d ranitidine bismuth	0.91 (0.82 to 0.99)	0.91 (0.82 to 0.99)	0.91 (0.82 to 0.99)	1.15 (1.02 to 1.25)
7d levofloxacin	0.80 (0.73 to 0.88)	0.80 (0.72 to 0.88)	0.80 (0.72 to 0.88)	1.04 (0.94 to 1.13)
10/14d levofloxacin	0.95 (0.89 to 1.02)	0.95 (0.88 to 1.02)	0.95 (0.88 to 1.02)	1.23 (1.14 to 1.30)
14d hybrid	0.94 (0.85 to 1.02)	0.94 (0.85 to 1.02)	0.94 (0.85 to 1.02)	1.20 (1.07 to 1.29)
10/14d sequential				
10/14d triple	0.93 (0.90 to 0.96)	0.93 (0.90 to 0.96)	0.93 (0.90 to 0.96)	0.93 (0.89 to 0.96)
10/14d bismuth	0.98 (0.94 to 1.01)	0.98 (0.94 to 1.01)	0.98 (0.94 to 1.02)	0.98 (0.93 to 1.02)
7d bismuth	0.90 (0.83 to 0.97)	0.90 (0.83 to 0.97)	0.90 (0.83 to 0.97)	0.91 (0.81 to 0.99)

	Full analysis	Sensitivity analysis (publication year)	Sensitivity analysis (quality of included study)	Sensitivity analysis (sample size)
Intervention	**Risk Ratio (95% CrI), random-effect model**	**Risk Ratio (95% CrI), random-effect model**	**Risk Ratio (95% CrI), random-effect model**	**Risk Ratio (95% CrI), random-effect model**
10/14d concomitant	1.04 (0.99 to 1.07)	1.04 (0.99 to 1.07)	1.03 (0.99 to 1.07)	1.02 (0.97 to 1.07)
7d probiotic	0.95 (0.89 to 1.01)	0.95 (0.88 to 1.00)	0.95 (0.88 to 1.01)	0.96 (0.89 to 1.03)
10/14d probiotic	1.03 (0.98 to 1.08)	1.03 (0.98 to 1.08)	1.03 (0.98 to 1.08)	1.04 (0.95 to 1.10)
7d ranitidine bismuth	0.93 (0.87 to 0.99)	0.93 (0.86 to 1.00)	0.94 (0.87 to 1.00)	0.95 (0.86 to 1.02)
10/14d ranitidine bismuth	0.98 (0.90 to 1.04)	0.98 (0.89 to 1.05)	0.98 (0.89 to 1.05)	0.97 (0.85 to 1.05)
7d levofloxacin	0.86 (0.79 to 0.93)	0.86 (0.79 to 0.93)	0.86 (0.79 to 0.93)	0.87 (0.79 to 0.95)
10/14d levofloxacin	1.03 (0.97 to 1.08)	1.03 (0.96 to 1.08)	1.03 (0.96 to 1.08)	1.03 (0.95 to 1.09)
14d hybrid	1.02 (0.93 to 1.08)	1.02 (0.93 to 1.08)	1.01 (0.93 to 1.08)	1.01 (0.90 to 1.08)
10/14d triple				
10/14d bismuth	1.05 (1.01 to 1.09)	1.05 (1.01 to 1.09)	1.06 (1.01 to 1.10)	1.05 (1.00 to 1.10)
7d bismuth	0.97 (0.89 to 1.04)	0.97 (0.89 to 1.04)	0.97 (0.89 to 1.05)	0.98 (0.88 to 1.06)
10/14d concomitant	1.11 (1.07 to 1.16)	1.11 (1.06 to 1.16)	1.11 (1.06 to 1.17)	1.10 (1.04 to 1.16)
7d probiotic	1.02 (0.95 to 1.08)	1.02 (0.95 to 1.08)	1.03 (0.95 to 1.10)	1.04 (0.95 to 1.11)
10/14d probiotic	1.11 (1.05 to 1.16)	1.11 (1.05 to 1.17)	1.11 (1.05 to 1.17)	1.12 (1.03 to 1.19)
7d ranitidine bismuth	1.00 (0.93 to 1.07)	1.00 (0.92 to 1.08)	1.01 (0.93 to 1.08)	1.02 (0.93 to 1.10)
10/14d ranitidine bismuth	1.05 (0.97 to 1.12)	1.06 (0.97 to 1.13)	1.05 (0.97 to 1.13)	1.04 (0.92 to 1.13)
7d levofloxacin	0.93 (0.85 to 1.00)	0.93 (0.85 to 1.00)	0.93 (0.85 to 1.01)	0.94 (0.85 to 1.03)

Intervention	Full analysis	Sensitivity analysis (publication year)	Sensitivity analysis (quality of included study)	Sensitivity analysis (sample size)
	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model
10/14d levofloxacin	1.10 (1.04 to 1.16)	1.10 (1.04 to 1.16)	1.11 (1.04 to 1.16)	1.11 (1.03 to 1.18)
14d hybrid	1.09 (1.00 to 1.16)	1.09 (0.99 to 1.17)	1.09 (0.99 to 1.17)	1.08 (0.97 to 1.17)
10/14d bismuth				
7d bismuth	0.92 (0.85 to 0.99)	0.92 (0.85 to 0.99)	0.92 (0.85 to 0.99)	0.93 (0.83 to 1.01)
10/14d concomitant	1.06 (1.01 to 1.11)	1.06 (1.01 to 1.11)	1.05 (1.00 to 1.11)	1.04 (0.98 to 1.10)
7d probiotic	0.97 (0.90 to 1.04)	0.97 (0.90 to 1.04)	0.97 (0.90 to 1.04)	0.98 (0.90 to 1.06)
10/14d probiotic	1.06 (1.00 to 1.12)	1.06 (1.00 to 1.12)	1.05 (0.99 to 1.11)	1.06 (0.97 to 1.14)
7d ranitidine bismuth	0.96 (0.88 to 1.02)	0.96 (0.88 to 1.03)	0.96 (0.88 to 1.03)	0.97 (0.88 to 1.05)
10/14d ranitidine bismuth	1.00 (0.92 to 1.08)	1.01 (0.91 to 1.08)	1.00 (0.91 to 1.07)	0.99 (0.87 to 1.08)
7d levofloxacin	0.89 (0.81 to 0.96)	0.89 (0.81 to 0.96)	0.88 (0.80 to 0.95)	0.89 (0.80 to 0.98)
10/14d levofloxacin	1.05 (0.99 to 1.11)	1.05 (0.99 to 1.11)	1.05 (0.98 to 1.11)	1.06 (0.98 to 1.13)
14d hybrid	1.04 (0.95 to 1.11)	1.04 (0.95 to 1.12)	1.03 (0.94 to 1.11)	1.03 (0.92 to 1.12)
7d bismuth				
10/14d concomitant	1.15 (1.06 to 1.25)	1.15 (1.06 to 1.26)	1.15 (1.06 to 1.25)	1.13 (1.02 to 1.26)
7d probiotic	1.05 (0.96 to 1.16)	1.05 (0.96 to 1.16)	1.06 (0.96 to 1.17)	1.06 (0.95 to 1.20)
10/14d probiotic	1.15 (1.05 to 1.26)	1.15 (1.05 to 1.26)	1.15 (1.05 to 1.26)	1.15 (1.02 to 1.29)
7d ranitidine bismuth	1.04 (0.94 to 1.14)	1.04 (0.94 to 1.15)	1.04 (0.94 to 1.15)	1.05 (0.93 to 1.18)

Intervention	Full analysis	Sensitivity analysis (publication year)	Sensitivity analysis (quality of included study)	Sensitivity analysis (sample size)
	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model
10/14d ranitidine bismuth	1.09 (0.97 to 1.20)	1.09 (0.97 to 1.21)	1.08 (0.97 to 1.20)	1.07 (0.92 to 1.22)
7d levofloxacin	0.96 (0.87 to 1.06)	0.96 (0.87 to 1.06)	0.96 (0.86 to 1.06)	0.97 (0.85 to 1.09)
10/14d levofloxacin	1.14 (1.04 to 1.25)	1.14 (1.04 to 1.25)	1.14 (1.04 to 1.25)	1.14 (1.02 to 1.28)
14d hybrid	1.13 (1.01 to 1.25)	1.13 (1.01 to 1.25)	1.12 (1.00 to 1.25)	1.11 (0.97 to 1.26)
10/14d concomitant				
7d probiotic	0.92 (0.85 to 0.98)	0.91 (0.85 to 0.98)	0.92 (0.85 to 0.99)	0.94 (0.86 to 1.02)
10/14d probiotic	1.00 (0.94 to 1.06)	1.00 (0.94 to 1.06)	1.00 (0.94 to 1.06)	1.02 (0.93 to 1.10)
7d ranitidine bismuth	0.90 (0.83 to 0.97)	0.90 (0.83 to 0.97)	0.91 (0.84 to 0.98)	0.93 (0.84 to 1.01)
10/14d ranitidine bismuth	0.95 (0.86 to 1.02)	0.95 (0.86 to 1.02)	0.95 (0.86 to 1.02)	0.95 (0.83 to 1.05)
7d levofloxacin	0.83 (0.76 to 0.90)	0.83 (0.76 to 0.90)	0.84 (0.76 to 0.91)	0.86 (0.77 to 0.94)
10/14d levofloxacin	0.99 (0.93 to 1.05)	0.99 (0.93 to 1.05)	0.99 (0.93 to 1.06)	1.01 (0.93 to 1.09)
14d hybrid	0.98 (0.90 to 1.05)	0.98 (0.90 to 1.05)	0.98 (0.89 to 1.05)	0.99 (0.89 to 1.07)
7d probiotic				
10/14d probiotic	1.09 (1.01 to 1.18)	1.09 (1.01 to 1.18)	1.09 (1.01 to 1.18)	1.08 (0.97 to 1.19)
7d ranitidine bismuth	0.99 (0.90 to 1.07)	0.99 (0.90 to 1.08)	0.99 (0.90 to 1.08)	0.98 (0.89 to 1.09)
10/14d ranitidine bismuth	1.03 (0.93 to 1.13)	1.04 (0.93 to 1.14)	1.03 (0.92 to 1.13)	1.01 (0.88 to 1.13)
7d levofloxacin	0.91 (0.82 to 1.00)	0.91 (0.82 to 1.00)	0.91 (0.82 to 1.00)	0.91 (0.81 to 1.01)

Intervention	Full analysis	Sensitivity analysis (publication year)	Sensitivity analysis (quality of included study)	Sensitivity analysis (sample size)
	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model
10/14d levofloxacin	1.08 (1.00 to 1.17)	1.08 (1.00 to 1.17)	1.08 0.99 to 1.17)	1.07 (0.97 to 1.18)
14d hybrid	1.07 (0.97 to 1.17)	1.07 (0.96 to 1.17)	1.07 (0.95 to 1.17)	1.05 (0.92 to 1.16)
10/14d probiotic				
7d ranitidine bismuth	0.90 (0.83 to 0.98)	0.90 (0.83 to 0.98)	0.91 (0.83 to 0.99)	0.91 (0.82 to 1.01)
10/14d ranitidine bismuth	0.95 (0.86 to 1.03)	0.95 (0.86 to 1.03)	0.95 (0.86 to 1.03)	0.93 (0.82 to 1.04)
7d levofloxacin	0.84 (0.76 to 0.91)	0.84 (0.76 to 0.91)	0.84 (0.76 to 0.91)	0.84 (0.75 to 0.94)
10/14d levofloxacin	0.99 (0.93 to 1.06)	0.99 (0.93 to 1.06)	0.99 (0.93 to 1.06)	1.00 (0.92 to 1.08)
14d hybrid	0.98 (0.89 to 1.06)	0.98 (0.89 to 1.06)	0.98 (0.89 to 1.06)	0.97 (0.86 to 1.08)
7d ranitidine bismuth				
10/14d ranitidine bismuth	1.05 (0.95 to 1.15)	1.05 (0.94 to 1.17)	1.04 (0.94 to 1.14)	1.02 (0.90 to 1.14)
7d levofloxacin	0.93 (0.84 to 1.02)	0.93 (0.83 to 1.03)	0.92 (0.83 to 1.02)	0.93 (0.82 to 1.04)
10/14d levofloxacin	1.10 (1.01 to 1.20)	1.10 (1.01 to 1.20)	1.09 (1.00 to 1.19)	1.09 (0.99 to 1.21)
14d hybrid	1.09 (0.98 to 1.19)	1.09 (0.97 to 1.20)	1.08 (0.97 to 1.19)	1.07 (0.93 to 1.19)
10/14d ranitidine bismuth				
7d levofloxacin	0.88 (0.79 to 0.99)	0.88 (0.79 to 0.99)	0.89 (0.79 to 0.99)	0.91 (0.79 to 1.04)
10/14d levofloxacin	1.05 (0.96 to 1.15)	1.05 (0.96 to 1.16)	1.05 (0.96 to 1.16)	1.07 (0.96 to 1.22)
14d hybrid	1.04 (0.93 to 1.15)	1.04 (0.92 to 1.16)	1.04 (0.93 to 1.16)	1.05 (0.91 to 1.20)

Intervention	Full analysis	Sensitivity analysis (publication year)	Sensitivity analysis (quality of included study)	Sensitivity analysis (sample size)
	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model	Risk Ratio (95% CrI), random-effect model
7d levofloxacin				
10/14d levofloxacin	1.19 (1.09 to 1.31)	1.19 (1.09 to 1.31)	1.19 (1.09 to 1.31)	1.18 (1.06 to 1.32)
14d hybrid	1.18 (1.05 to 1.31)	1.18 (1.05 to 1.31)	1.17 (1.04 to 1.31)	1.16 (1.01 to 1.30)
10/14d levofloxacin				
14d hybrid	0.99 (0.90 to 1.07)	0.99 (0.89 to 1.08)	0.99 (0.89 to 1.08)	0.98 (0.86 to 1.08)

CrI=credible interval;

See Table 1 for key of intervention regimen names and descriptions.

Table S4.2 Traditional meta-analysis results

	Studies	Participants	Statistical Method	Effect Estimate	Heterogeneity
7d concomitant VS. 7d triple	1	119	Risk Ratio (M-H, Random, 95% CI)	1.39 (1.16 to 1.67)	Not applicable
10/14d sequential VS. 7d triple	15	3713	Risk Ratio (M-H, Random, 95% CI)	1.22 (1.19 to 1.27)	P = 0.67; I^2 =0%
10/14d triple VS. 7d triple	32	6844	Risk Ratio (M-H, Random, 95% CI)	1.08 (1.05 to 1.12)	P = 0.10; I^2 =25%
10/14d bismuth VS. 7d triple	6	1188	Risk Ratio (M-H, Random, 95% CI)	1.27 (1.04 to 1.55)	P<0.00001; I^2 =88%
7d bismuth VS. 7d triple	8	1340	Risk Ratio (M-H, Random, 95% CI)	1.07 (1.00 to 1.15)	P = 0.13; I^2 =38%
7d probiotic VS.7d triple	11	2392	Risk Ratio (M-H, Random, 95% CI)	1.14 (1.09 to 1.19)	P = 0.83; I^2 =0%
10/14d probiotic VS.7 triple	1	33	Risk Ratio (M-H, Random, 95% CI)	1.13 (0.69 to 1.84)	Not applicable
7d ranitidine bismuth VS. 7d triple	11	1839	Risk Ratio (M-H, Random, 95% CI)	1.10 (1.04 to 1.16)	P = 0.16; I^2 =30%
7d levofloxacin VS.7d triple	8	2329	Risk Ratio (M-H, Random, 95% CI)	1.01 (0.92 to 1.10)	P<0.00001; I^2 =77%
10/14d triple VS. 7d concomitant	2	265	Risk Ratio (M-H, Random, 95% CI)	0.88 (0.74 to 1.03)	P = 0.06; I^2 =72%
10/14d concomitant VS. 7d concomitant	1	180	Risk Ratio (M-H, Random, 95% CI)	0.99 (0.89 to 1.09)	Not applicable
7d ranitidine bismuth VS. 7d concomitant	1	55	Risk Ratio (M-H, Random, 95% CI)	0.90 (0.79 to 1.04)	Not applicable
10/14d triple VS. 10/14d sequential	18	5032	Risk Ratio (M-H, Random, 95% CI)	0.91 (0.86 to 0.96)	P<0.00001; I^2 =70%
10/14d bismuth VS. 10/14d sequential	4	1011	Risk Ratio (M-H, Random, 95% CI)	1.01 (0.96 to 1.06)	P = 0.37; I^2 =5%
10/14d concomitant VS. 10/14d sequential	5	921	Risk Ratio (M-H, Random, 95% CI)	1.05 (1.00 to 1.10)	P = 0.54; I^2 =0%
7d levofloxacin VS. 10/14d sequential	1	229	Risk Ratio (M-H, Random, 95% CI)	1.00 (0.87 to 1.14)	Not applicable
10/14d levofloxacin VS.10/14d sequential	1	230	Risk Ratio (M-H, Random, 95% CI)	1.06 (0.92 to 1.21)	Not applicable
14d hybrid VS. 10/14d sequential	2	600	Risk Ratio (M-H, Random, 95% CI)	1.02 (0.77 to 1.34)	P=0.0002; I^2 =93%
10/14d bismuth VS. 10/14d triple	9	1844	Risk Ratio (M-H, Random, 95% CI)	0.99 (0.88 to 1.12)	P<0.0001; I^2 =78%
10/14d concomitant VS. 10/14d triple	3	506	Risk Ratio (M-H, Random, 95% CI)	1.23 (1.13 to 1.34)	P = 0.85; I^2 =0%
10/14d probiotic VS.10/14d triple	5	687	Risk Ratio (M-H, Random, 95% CI)	1.16 (1.07 to 1.27)	P = 0.26; I^2 =25%
7d ranitidine bismuth VS. 10/14d triple	1	90	Risk Ratio (M-H, Random, 95% CI)	0.98 (0.85 to 1.13)	Not applicable
10/14d ranitidine bismuth VS. 10/14d triple	5	948	Risk Ratio (M-H, Random, 95% CI)	1.09 (0.98 to 1.20)	P = 0.17; I^2 =37%
10/14d levofloxacin VS. 10/14d triple	3	554	Risk Ratio (M-H, Random, 95% CI)	1.16 (1.06 to 1.27)	P = 0.46; I^2 =0%
7d bismuth VS. 10/14d bismuth	3	404	Risk Ratio (M-H, Random, 95% CI)	0.89 (0.81 to 0.97)	P = 0.45; I^2 =0%
10/14d concomitant VS. 10/14d bismuth	2	360	Risk Ratio (M-H, Random, 95% CI)	0.93 (0.84 to 1.03)	P = 0.93; I^2 =0%
10/14d probiotic VS. 10/14d bismuth	1	294	Risk Ratio (M-H, Random, 95% CI)	1.35 (1.22 to 1.48)	Not applicable
10/14d levofloxacin VS. 10/14d bismuth	1	161	Risk Ratio (M-H, Random, 95% CI)	0.95 (0.83 to 1.08)	Not applicable

	Studies	Participants	Statistical Method	Effect Estimate	Heterogeneity
7d levofloxacin VS. 7d bismuth	2	225	Risk Ratio (M-H, Random, 95% CI)	0.96 (0.80 to 1.15)	P = 0.19; I^2 =41%
14d hybrid VS. 10/14d concomitant	1	340	Risk Ratio (M-H, Random, 95% CI)	0.98 (0.92 to 1.05)	Not applicable
10/14d probiotic VS. 7d probiotic	1	49	Risk Ratio (M-H, Random, 95% CI)	1.33 (0.85 to 2.08)	Not applicable
10/14d levofloxacin VS. 10/14d probiotic	1	193	Risk Ratio (M-H, Random, 95% CI)	1.19 (1.03 to 1.38)	Not applicable
10/14d ranitidine bismuth VS. 7d ranitidine bismuth	1	110	Risk Ratio (M-H, Random, 95% CI)	1.02 (0.87 to 1.20)	Not applicable
10/14d levofloxacin VS. 7d levofloxacin	1	105	Risk Ratio (M-H, Random, 95% CI)	1.09 (0.96 to 1.23)	Not applicable

CI=confidence interval; M-H=Mantel-Haenszel (test).

See Table 1 for key of intervention regimen names and descriptions.

Fig S4.1 Assessment of publication bias-Funnel plot of eradication therapies for *H. pylori* by ITT analysis



See Table 1 for key of intervention regimen names and descriptions.

Table S4.3 Eradication rates for each country.

Interventions	Eradication rates mean (95% CrI)						
	China	**Korea**	**Iran**	**Italy**	**Turkey**	**India**	**Spain**
A) 7d triple	0.74 (0.69 to 0.79)*	0.71(0.68 to 0.74)*	0.80 (0.41 to 0.97)	0.71 (0.68 to 0.74)*	0.36 (0.20 to 0.55)*	0.15 (0.00 to 0.58)	0.75 (0.71 to 0.79)*
B) 7d concomitant	NA	NA	NA	NA	0.98 (0.67 to 1.00)	NA	NA
C) 10/14d sequential	0.87 (0.80 to 0.93)	0.83 (0.78 to 0.87)	0.80 (0.75 to 0.84)	0.92 (0.88 to 0.94)	NA	0.83 (0.62 to 0.94)	0.87 (0.74 to 0.95)
D) 10/14d triple	0.76 (0.60 to 0.88)	0.78 (0.72 to 0.83)	0.88 (0.68 to 0.97)	0.78 (0.73 to 0.83)	0.58 (0.49 to 0.66)	0.75 (0.65 to 0.83)*	0.79 (0.67 to 0.88)
E) 10/14d bismuth	0.90 (0.83 to 0.95)	NA	0.79 (0.57 to 0.93)*	NA	0.72 (0.60 to 0.82)	0.60 (0.18 to 0.92)	NA
F) 7d bismuth	0.83 (0.73 to 0.90)	0.62(0.40 to 0.80)	0.76 (0.34 to 0.97)	NA	NA	NA	0.80 (0.64 to 0.91)
G) 10/14d concomitant	NA	0.86 (0.72 to 0.94)	0.69 (0.25 to 0.95)	0.83 (0.44 to 0.99)	0.65 (0.41 to 0.85)	NA	0.91 (0.79 to 0.97)
H) 7d probiotic	0.86 (0.70 to 0.96)	0.80 (0.73 to 0.85)	NA	0.77 (0.67 to 0.86)	NA	NA	NA
J) 10/14d probiotic	NA	NA	0.95 (0.77 to 1.00)	0.84 (0.62 to 0.96)	0.74 (0.60 to 0.86)	NA	NA
K) 7d ranitidine bismuth	0.86 (0.73 to 0.94)	NA	NA	0.72 (0.61 to 0.82)	0.44 (0.09 to 0.85)	NA	0.81 (0.72 to 0.89)
L) 10/14d ranitidine bismuth	NA	NA	NA	0.74 (0.47 to 0.92)	0.67 (0.53 to 0.80)	NA	NA
M) 7d levofloxacin	0.78 (0.66 to 0.87)	0.57 (0.37 to 0.74)	NA	0.78 (0.68 to 0.85)	NA	NA	NA
N) 10/14d levofloxacin	0.85 (0.60 to 0.96)	NA	NA	NA	0.86 (0.69 to 0.96)	0.81 (0.45 to 0.97)	0.88 (0.76 to 0.95)
P) 14d hybrid	NA	NA	0.90 (0.68 to 0.98)	0.79 (0.59 to 0.92)	NA	NA	0.88 (0.68 to 0.98)

CrI=credible interval;
See Table 1 for key of intervention regimen names and descriptions.
Note: * indicates the group is the reference group in this country.